Texto: 
bilateral mastectomy was advised.
bilateral circumscribed masses, the mass on left is associated with pleomorphic calcifications.
bilateral breast carcinoma
-fibroadenoma
-cysts
-malignancy (primary or metastatic)
asymptomatic.
pathologic diagnosis on both left and right side: papillary carcinoma in situ,lobular carcinoma and ductal carcinoma in situ.  
the patient in the above case has elected to have breast conserving therapy, despite recommendation for bilateral mastectomy. 
in a recent study based in the netherlands*, patients with synchronous breast cancer (defined as bilateral breast cancer – bbc - cancer diagnosed in both breasts at the same time or within a period of 3 months of diagnosis of the first tumor) had a worse prognosis and survival than in patients with unilateral breast cancer (ubc).   patients with bbc showed a higher proportion of tubular carcinoma and medially located tumors, a greater 5- and 10-year local recurrence rate and nearly double the 5- and 10-year distant metastasis rate.
as synchronous breast carcinoma represents a minority of cases (1.5%), it’s optimal management continues to be under debate.

*synchronous, bilateral breast cancer: prognostic value and incidence,  the breast, volume 12, issue 2 , april 2003, pages 83-88


Keywords by value: 
- breast: 0.11309624910602878 (1038)
- synchronous: 0.0999447183342593 (10)
- bbc: 0.079062945506426 (2)
- 5-: 0.07284637886463276 (630)
- 10-year: 0.07284637886463276 (9)
- carcinoma: 0.06516397318428341 (1515)
- cancer: 0.06298576825929966 (830)
- bilateral: 0.05579778643895365 (2204)
- situ: 0.049842348752870094 (137)
- mastectomy: 0.045541244894019096 (52)
- *: 0.04264641626385721 (276)
- -cysts: 0.039531472753213 (1)
- 83-88: 0.039531472753213 (1)
- netherlands: 0.03642318943231638 (2)
- conserving: 0.03460496024797483 (4)
- -fibroadenoma: 0.03331490611141977 (4)
- ubc: 0.03331490611141977 (628)
- minority: 0.03231426238355335 (5)
- -malignancy: 0.030805418273144328 (8)
- pages: 0.03020662279052315 (14)
- rate: 0.029871941618617427 (5034)
- patients: 0.029752124655148333 (1457)
- debate: 0.029678447742736674 (14)
- proportion: 0.029205979062656737 (23)
- optimal: 0.02769713495224771 (29)
- elected: 0.02738774987831519 (67)
- april: 0.02738774987831519 (26)
- recommendation: 0.026826480178969873 (47)
- issue: 0.026570164421840063 (1710)
- prognostic: 0.02567029583232369 (30)
- advised: 0.024132426993189918 (36)
- breasts: 0.02371819685807326 (45)
- distant: 0.0223626772532619 (58)
- medially: 0.021812891055538432 (67)
- value: 0.021727473140871645 (226)
- lobular: 0.0216436519166019 (121)
- pleomorphic: 0.021561368783560658 (76)
- nearly: 0.021097060806247476 (66)
- survival: 0.020544448068920352 (108)
- continues: 0.01999466187119689 (86)
- both: 0.01957130036489795 (1020)
- papillary: 0.019453729190530455 (172)
- 2003: 0.01925439393236528 (136)
- 1.5: 0.019157953550208495 (160)
- unilateral: 0.01901707374647137 (146)
- higher: 0.018791684352835097 (109)
- double: 0.018535368595705284 (202)
- represents: 0.018412503240601633 (129)
- prognosis: 0.018176432686855346 (166)
- volume: 0.018100425698901204 (189)
- ductal: 0.018062899915625347 (260)
- period: 0.017915860351396688 (199)
- tubular: 0.01784410994177139 (175)
- despite: 0.017808660706313484 (137)
- local: 0.017601656034729796 (390)
- diagnosis: 0.017598379648254888 (1487)
- incidence: 0.017568065578545233 (176)
- –: 0.017245314459150212 (572)
- circumscribed: 0.017032460032069836 (255)
- worse: 0.016973455168493554 (520)
- pathologic: 0.016772845779070275 (313)
- under: 0.016744906094089844 (1187)
- recurrence: 0.01671713941136374 (207)
- defined: 0.016146110611468666 (376)
- same: 0.015794679817228728 (239)
- located: 0.015772202051203863 (256)
- 12: 0.015683401031938483 (1027)
- based: 0.014612961265771123 (378)
- ,: 0.014567357785683627 (45533)
- management: 0.014459782257648615 (356)
- tumors: 0.014393346895383413 (533)
- greater: 0.014393346895383413 (379)
- metastasis: 0.014344158413901017 (332)
- calcifications: 0.014247371097007858 (461)
- diagnosed: 0.014090561241233208 (363)
- above: 0.01404456796694088 (359)
- side: 0.013275544850959959 (2155)
- in: 0.013227715744312935 (113220)
- (: 0.012957161008858485 (9594)
- masses: 0.012953329138995906 (522)
- asymptomatic: 0.012953329138995906 (453)
- recent: 0.012882148201075323 (581)
- first: 0.01285867011114732 (475)
- ): 0.012798882369745383 (10569)
- cases: 0.012765967999915391 (558)
- study: 0.012608212362600714 (612)
- showed: 0.012564140214904469 (635)
- as: 0.011592623371247782 (55990)
- ’: 0.011453034706930295 (1174)
- primary: 0.011351498936752002 (748)
- s: 0.010989989538630436 (414481)
- time: 0.010823323888965527 (1157)
- a: 0.010670846685702277 (549576)
- months: 0.010466104460493576 (910)
- therapy: 0.010245025992110373 (1469)
- :: 0.01013699386538713 (11095)
- than: 0.010040577824745623 (1107)
- metastatic: 0.009646230509489194 (1079)
- associated: 0.009042433013039022 (1317)
- or: 0.008982266806849395 (60128)
- 3: 0.008972984424693003 (8405)
- %: 0.008938659342358778 (2175)
- tumor: 0.008933777137268211 (2333)
- it: 0.008613669885798281 (53878)
- left: 0.008574935150429728 (7401)
- case: 0.008383427950077448 (2053)
- have: 0.008297928602534043 (1751)
- had: 0.008268384839644432 (2121)
- 2: 0.008251589670450879 (13754)
- -: 0.008214028962817773 (21459)
- within: 0.007310006315632653 (1927)
- has: 0.007195963993247883 (2768)
- on: 0.006492296075026261 (91641)
- and: 0.006457722178734294 (31978)
- be: 0.005909222974636454 (14541)
- mass: 0.005329421555818675 (5255)
- at: 0.005191763017182211 (83424)
- the: 0.004959615594748908 (67588)
- was: 0.00443173776777438 (7680)
- right: 0.004043191520674515 (8044)
- patient: 0.0038412194211497218 (8535)
- to: 0.003830207250609742 (40381)
- for: 0.0032695432674561217 (12260)
- of: 0.0026121928430042247 (41955)
- is: 0.0025214833111422675 (65037)
- with: 0.0020987296159621477 (23954)
- .: 0.0012735259586491936 (82185)
